EQS-News: Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

EQS-News: Cardiol Therapeutics
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

16.12.2022 / 18:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

News Source: News Direct

16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com